KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Research & Development (2016 - 2025)

Novavax (NVAX) has 16 years of Research & Development data on record, last reported at $75.9 million in Q4 2025.

  • For Q4 2025, Research & Development fell 27.31% year-over-year to $75.9 million; the TTM value through Dec 2025 reached $342.3 million, down 12.49%, while the annual FY2025 figure was $342.3 million, 12.49% down from the prior year.
  • Research & Development reached $75.9 million in Q4 2025 per NVAX's latest filing, down from $98.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $963.0 million in Q4 2021 and bottomed at $75.9 million in Q4 2025.
  • Average Research & Development over 5 years is $262.0 million, with a median of $192.1 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 3407.97% in 2021, then crashed 73.22% in 2022.
  • A 5-year view of Research & Development shows it stood at $963.0 million in 2021, then plummeted by 73.22% to $257.8 million in 2022, then plummeted by 36.13% to $164.7 million in 2023, then tumbled by 36.62% to $104.4 million in 2024, then decreased by 27.31% to $75.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $75.9 million in Q4 2025, $98.3 million in Q3 2025, and $79.2 million in Q2 2025.